ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T-cell therapeutics.
ImmunoScape leverages computational biology and machine learning, together with high throughput screening and evaluation of T-cell clones, to efficiently identify novel T-cell therapy targets and TCR candidates.
ImmunoScape was founded in Singapore in 2016 by Choon Peng Ng, Alessandra Nardin and Evan Newell. The company is headquartered in Singapore, with an office in San Diego, California.
ImmunoScape's Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, and visualization tools to provide novel, reproducible immune profiling information.
ImmunoScape’s TargetScape® technology can be used to detect rare antigen specific T-cells with frequencies as low as 1 in 100,000 CD8+ cells, and simultaneously provide comprehensive phenotypic information for these antigen specific T cells.
ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic.
ImmunoScape is backed by Anzu Partners, University of Tokyo Edge Capital Partners (UTEC), EDBI, Amgen Ventures, and others. The company raised $14M in a new round on Sep 20, 2022. This brings ImmunoScape's total funding to $42M to date.